| 1141. Phase 3 Trial (in progress) of the SYK Inhibitor Fostamatinib in Patients Hospitalized with COVID-19: Protocol and Study Implementation Updates L Yan, Z Mallat, SM Lobo, A Malik, W Dummer Open Forum Infectious Diseases 9 (Supplement_2), ofac492. 979, 2022 | | 2022 |
| 165: GOAL-DIRECTED THERAPY DOES NOT REVERSE AKI IN CRITICALLY ILL PATIENTS BUT DECREASES MORTALITY. C Amendola, J Silva, T Carvalho, E Lima, E Burdmann, L Malbouisson, ... Critical Care Medicine 42 (12), A1400, 2014 | | 2014 |
| 561. Phase 3 trial of fostamatinib for the treatment of COVID-19: repurposing an immunomodulatory drug previously approved for immune thrombocytopenia Z Mallat, SM Lobo, A Malik, S Tong Open Forum Infectious Diseases 8 (Suppl 1), S382, 2021 | 3 | 2021 |
| A Comparison between Low and High-dose of Hydroxyethylstarch Solution in Resuscitation for Shock induced by Ischemia/Reperfusion in Rabbits Z Tu, Q Sun, G Dimopoulos, SM Lobo, D De Backer, X Xiao, JL Vincent EXCLI Journal 5, 46-54, 2006 | | 2006 |
| A global survey of the effect of COVID-19 on critical care training S Wahlster, M Sharma, B Çoruh, JA Town, A Lewis, SM Lobo, IS Maia, ... ATS scholar 2 (4), 508-520, 2021 | 9 | 2021 |
| A multicentre, prospective study to evaluate costs of septic patients in Brazilian intensive care units AMC Sogayar, FR Machado, A Rea-Neto, A Dornas, CMC Grion, ... Pharmacoeconomics 26, 425-434, 2008 | 190 | 2008 |
| A worldwide perspective of sepsis epidemiology and survival according to age: Observational data from the ICON audit K Kotfis, X Wittebole, U Jaschinski, J Solé-Violán, R Kashyap, M Leone, ... Journal of critical care 51, 122-132, 2019 | 40 | 2019 |
| Abstract P34: Health care disparities and outcomes of cancer patients with COVID-19: A pooled analysis of two Brazilian tertiary centers M Topanotti, LL Furlan, C Marchon, P Amaral, BC Beneton, LA Fadul, ... Clinical Cancer Research 27 (6_Supplement), P34-P34, 2021 | | 2021 |
| Acadêmica, Faculdade de Medicina de São José do Rio Preto-São José do Rio Preto (SP), Brasil 2 Unidade de Terapia Intensiva, Hospital de Base de São José do Rio Preto … ÉE de Freitas, JV Gandolfi, SMA Lobo | | |
| Acidentes ofídicos causados por Bothrops moojeni na regiäo de Säo José do Rio Preto-Säo Paulo JA Kouyoumdjian, C Polizelli, SMA Lobo, SM Guimaräes Arq. bras. med, 167-71, 1990 | 20 | 1990 |
| Admission CRP levels are correlated with mortality and organ failure. SMA Lobo, FRM Lobo, DP Bota, F Ferreira, C Melot, JL Vincent CRITICAL CARE MEDICINE 28 (12), A192-A192, 2000 | 2 | 2000 |
| Adverse outcomes of delayed intensive care unit FRQ Santos, MN Machado, SMA Lobo Revista Brasileira de Terapia Intensiva 32, 92-98, 2020 | 14* | 2020 |
| AMB Guidelines: COVID–19 LL Ferreira, DL Sampaio, ACP Chagas, HP Guimarães, LA Hajjar, ... Revista da associacao medica brasileira 66, 17-21, 2020 | 3 | 2020 |
| An epidemiological study of sepsis in ICUs: Sepsis Brazil Study J Sales, C David, P Souza, M Knibel, R Hatum, G Moraes, F Dias, ... Critical Care 10 (Suppl 1), P111, 2006 | 1 | 2006 |
| Anemia and blood transfusion in a surgical intensive care unit Y Sakr, S Lobo, S Knuepfer, E Esser, M Bauer, U Settmacher, D Barz, ... Critical care 14, 1-10, 2010 | 150 | 2010 |
| ANEMIA AND BLOOD TRANSFUSION IN A SURGICAL INTENSIVE CARE UNIT S Knuepfer, S Lobo, E Esser, M Bauer, U Settmacher, D Barz, K Reinhart, ... INTENSIVE CARE MEDICINE 35, 135-135, 2009 | | 2009 |
| Anemia e transfusão de hemácias em pacientes críticos S Lobo Rev Bras Ter Intensiva 16 (1), 7-8, 2004 | 7 | 2004 |
| Anemia e transfusões de concentrados de hemácias em pacientes graves nas UTI brasileiras (pelo FUNDO-AMIB) SM Lobo, SR Vieira, MF Knibel, CMC Grion, G Friedman, JL Valiatti, ... Revista Brasileira de Terapia Intensiva 18, 234-241, 2006 | 28 | 2006 |
| Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo … APJ Vlaar, M Witzenrath, P van Paassen, LMA Heunks, B Mourvillier, ... The Lancet Respiratory Medicine 10 (12), 1137-1146, 2022 | 70 | 2022 |
| Anti-C5a Vilobelimab Reduces All-cause Mortality in Critically Ill COVID-19 Patients and in Those With Severe ARDS: A Phase 3 Randomized Double-blind, Placebo-controlled Study M Witzenrath, APJ Vlaar, M Bauer, D Annane, L Heunks, B Mourvillier, ... D16. ADVANCING THE SCIENCE OF ARDS AND ACUTE RESPIRATORY FAILURE, A6237-A6237, 2023 | | 2023 |
Jean-Louis VincentUniversité libre de Bruxelles在 ulb.ac.be 的电子邮件经过验证
